India Globalization Capital Inc - Asset Resilience Ratio
India Globalization Capital Inc (IGC) has an Asset Resilience Ratio of 11.60% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IGC working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how India Globalization Capital Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of India Globalization Capital Inc.
Liquid Assets Composition Over Time
This chart breaks down India Globalization Capital Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore India Globalization Capital Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $1.10 Million | 11.34% |
| Short-term Investments | $25.00K | 0.26% |
| Total Liquid Assets | $1.13 Million | 11.60% |
Asset Resilience Insights
- Moderate Liquidity: India Globalization Capital Inc has 11.60% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
India Globalization Capital Inc Industry Peers by Asset Resilience Ratio
Compare India Globalization Capital Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 72.23% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for India Globalization Capital Inc (2006–2025)
The table below shows the annual Asset Resilience Ratio data for India Globalization Capital Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 4.63% | $405.00K | $8.75 Million | -7.47pp |
| 2024-03-31 | 12.10% | $1.20 Million | $9.90 Million | -7.40pp |
| 2023-03-31 | 19.50% | $3.35 Million | $17.18 Million | -19.48pp |
| 2022-03-31 | 38.98% | $10.46 Million | $26.83 Million | -1.80pp |
| 2021-03-31 | 40.78% | $14.63 Million | $35.87 Million | -1.79pp |
| 2020-03-31 | 42.57% | $12.34 Million | $28.98 Million | -34.00pp |
| 2019-03-31 | 76.57% | $26.39 Million | $34.47 Million | +59.93pp |
| 2018-03-31 | 16.65% | $1.81 Million | $10.85 Million | -4.78pp |
| 2017-03-31 | 21.43% | $2.42 Million | $11.28 Million | +21.34pp |
| 2016-03-31 | 0.09% | $17.17K | $18.86 Million | -0.15pp |
| 2015-03-31 | 0.24% | $49.54K | $20.33 Million | +0.04pp |
| 2014-03-31 | 0.20% | $35.69K | $17.73 Million | +0.11pp |
| 2013-03-31 | 0.09% | $16.85K | $19.25 Million | -- |
| 2012-03-31 | 0.00% | $0.00 | $25.26 Million | -- |
| 2008-03-31 | 4.44% | $3.00 Million | $67.63 Million | -89.08pp |
| 2007-03-31 | 93.52% | $66.10 Million | $70.69 Million | -6.33pp |
| 2006-03-31 | 99.84% | $65.83 Million | $65.93 Million | -- |
About India Globalization Capital Inc
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatm… Read more